New Frontiers of Drug Discovery - From Machine Learning to Physics

Описание: Join us in a discussion with Jonah Kallenbach, CEO of Reverie Labs, and Dr. Woody Sherman, CSO of Silicon Therapeutics, as they share their insights and outlook for computational drug discovery.

In this video, we show how machine learning and physics-based computational methods are transforming drug discovery and advancing best-in-class candidates toward the clinic.

Join our expert panel:

Jonah Kallenbach — Co-founder & CEO of Reverie Labs, a startup applying ML to optimize kinase inhibitors for oncology.
Dr. Woody Sherman — Chief Computational Scientist at Roivant Sciences, formerly of Silicon Therapeutics, pioneering physics-driven discovery with molecular dynamics, quantum mechanics, and AI.

Key topics covered:
How AI/ML platforms are accelerating drug design and lead optimization
Physics-based simulation at scale: molecular dynamics, free energy calculations, and quantum methods
The challenges and opportunities in kinase inhibitor design
Building collaborative pipelines that unify experimental and computational science
The role of data quality, APIs, and informatics platforms like CDD Vault in enabling integrated workflows
Cultural and organizational shifts needed to make computation central to decision-making

Who should watch: Computational chemists, drug discovery scientists, data scientists, and anyone interested in how ML, AI, and physics simulations are reshaping R&D.